Partnerships Target Autoimmune Diseases | Chemical & Engineering News
Volume 93 Issue 9 | p. 16 | Concentrates
Issue Date: March 2, 2015

Partnerships Target Autoimmune Diseases

Department: Business
Keywords: ROR gamma, autoimmune disease

Two big drug companies have struck pacts with biotech firms pursuing small-molecule inhibitors of retinoic acid-related orphan nuclear receptor gamma (RORγ). AstraZeneca signed a three-year collaboration with the British biotech Orca Pharmaceuticals in which it will gain access to inhibitors that Orca developed for autoimmune conditions such as arthritis and psoriasis. Sanofi’s agreement with the Dutch firm Lead Pharma is also around small molecules directed against RORγ for the treatment of autoimmune diseases.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment